Gemzar and Diffuse interstitial lung disease - a phase IV clinical study of FDA data

Summary:

Diffuse interstitial lung disease is reported as a side effect among people who take Gemzar (gemcitabine hydrochloride), especially for people who are male, 60+ old, have been taking the drug for 1 - 6 months also take Taxotere, and have Lung cancer - non-small cell.

The phase IV clinical study analyzes which people have Diffuse interstitial lung disease when taking Gemzar. It is created by eHealthMe based on reports of 20,184 people who have side effects when taking Gemzar from the FDA, and is updated regularly.

What is Gemzar?

Gemzar has active ingredients of gemcitabine hydrochloride. It is often used in pancreatic carcinoma. eHealthMe is studying from 20,315 Gemzar users. Check the latest studies of Gemzar.

What is Diffuse interstitial lung disease?

Diffuse interstitial lung disease (group of lung diseases affecting the interstitium) is found to be associated with 231 drugs and 799 conditions by eHealthMe. Check the latest studies of Diffuse interstitial lung disease.

On Jul, 03, 2026

20,184 people reported to have side effects when taking Gemzar.
Among them, 29 people (0.14%) have Diffuse interstitial lung disease.

Could Gemzar cause Diffuse interstitial lung disease?

Among these 29 people:

How long have people been on Gemzar when they have Diffuse interstitial lung disease? *

What is the gender of people who have Diffuse interstitial lung disease when taking Gemzar? *

female: 27.59 %
male: 72.41 %

What is the age of people who have Diffuse interstitial lung disease when taking Gemzar? *

What are other drugs people take besides Gemzar? *

What are other side effects people have besides Diffuse interstitial lung disease? *

Pneumonia: 8 people, 27.59%
Dyspnea (difficult or laboured breathing): 8 people, 27.59%
Leukopenia (less number of white blood cells in blood): 4 people, 13.79%
Ards (Acute Respiratory Distress Syndrome) (sudden failure of the respiratory (breathing) system): 4 people, 13.79%
High Blood Pressure: 3 people, 10.34%
Respiratory Acidosis (respiratory failure or ventilatory failure, causes the ph of blood and other bodily fluids to decrease): 3 people, 10.34%
Lung Disorder (lung disease): 3 people, 10.34%
Interstitial Lung Disease: 3 people, 10.34%
Idiopathic Pulmonary Fibrosis (chronic lung disease): 3 people, 10.34%
Fever: 3 people, 10.34%

What are the existing conditions these people have? *

Lung Cancer - Non-Small Cell (lung cancer): 5 people, 17.24%
Ovarian Cancer (cancer of ovary): 3 people, 10.34%
Peritoneal Mesothelioma Malignant (cancer of the mesothelium of peritoneal): 2 people, 6.90%
Bronchial Carcinoma (lung cancer): 2 people, 6.90%
Adenocarcinoma (malignant tumour formed from glandular structures in epithelial tissue): 2 people, 6.90%
Pleural Neoplasm (tumour of membranes around the lungs): 1 person, 3.45%
Pancreatic Carcinoma Metastatic (pancreatic cancer- metastatic): 1 person, 3.45%
Non-Small Cell Lung Cancer Recurrent (type of epithelial lung cancer reoccurrence): 1 person, 3.45%
Malignant Neoplasm Of Ampulla Of Vater (cancer tumour of union of the pancreatic duct and the common bile duct): 1 person, 3.45%
Malignant Hepatobiliary Neoplasm (cancer tumour of liver and intrahepatic bile ducts): 1 person, 3.45%

* Approximation only. Some reports may have incomplete information.

Do you take Gemzar and have Diffuse interstitial lung disease?

- Check whether Diffuse interstitial lung disease is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Gemzar:

Gemzar (20,315 reports)

Browse all side effects of Gemzar:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Diffuse interstitial lung disease:

Diffuse interstitial lung disease (231 drugs)

Browse all the conditions that are associated with Diffuse interstitial lung disease:

Diffuse interstitial lung disease (799 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on gemcitabine hydrochloride (the active ingredients of Gemzar) and Gemzar (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.